tldrdaily.news logo

FDA Advisers Reject GSK's Blood Cancer Drug Blenrep Over Safety Concerns

1 min read
Source: STAT
FDA Advisers Reject GSK's Blood Cancer Drug Blenrep Over Safety Concerns
Photo: STAT
TL;DR Summary

FDA advisers have voted that the risks of GSK's blood cancer drug Blenrep outweigh its benefits due to serious eye-related side effects and dosing concerns, potentially impacting its approval decision next week.

Topics:business#blenrep#blood-cancer#fda#gsk#health#side-effects
Share this article
  1. FDA advisers say risks of GSK blood cancer drug outweigh benefits in surprise setback  STAT
  2. FDA Committee Votes Against GSK Blood Cancer Drug Blenrep  The Wall Street Journal
  3. FDA’s ODAC Votes Against Risk:Benefit Profiles of Belantamab Mafodotin Combos in R/R Myeloma  OncLive
  4. GSK's blood cancer drug fails to secure US FDA advisers' support  Reuters
  5. GSK's bid to revive Blenrep hits snag after negative FDA adcom  FirstWord Pharma

Reading Insights

Total Reads

0

Unique Readers

0

Time Saved

1 min

vs 1 min read

Condensed

83%

193 → 32 words

Want the full story? Read the original article

Read on STAT